BRAF and astrocytoma (excluding glioblastoma): This drug’s function has more recently been shown to be successful in BRAF p.V600E mutated pediatric malignant astrocytomas, while less data is currently available on its use in LGG patients, of which there are more studies on the combination of dabrafenib and trametinib (Table 3) (88, 106, 198–200, 205).